AGÕæÈ˹ٷ½

STOCK TITAN

Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Virax Biolabs (NASDAQ: VRAX) has received a notification from Nasdaq on July 14, 2025, regarding non-compliance with the minimum bid price requirement. The company's stock has traded below the required $1.00 minimum bid price for 30 consecutive business days.

The biotechnology company has been granted a 180-day compliance period until January 12, 2026, to regain compliance. Virax can achieve compliance if its stock maintains a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. If unsuccessful, the company may be eligible for an additional 180-day grace period. Meanwhile, VRAX shares will continue trading on Nasdaq without interruption.

Virax Biolabs (NASDAQ: VRAX) ha ricevuto una comunicazione da Nasdaq il 14 luglio 2025 riguardo al mancato rispetto del requisito minimo del prezzo di offerta. Il titolo della società è stato scambiato al di sotto del prezzo minimo di offerta di $1,00 per 30 giorni lavorativi consecutivi.

La società biotecnologica ha ottenuto un periodo di conformità di 180 giorni fino al 12 gennaio 2026 per tornare in regola. Virax potrà raggiungere la conformità se il prezzo di chiusura del titolo rimane almeno a $1,00 per un minimo di 10 giorni lavorativi consecutivi. In caso contrario, l’azienda potrebbe beneficiare di un ulteriore periodo di grazia di 180 giorni. Nel frattempo, le azioni VRAX continueranno a essere negoziate su Nasdaq senza interruzioni.

Virax Biolabs (NASDAQ: VRAX) recibió una notificación de Nasdaq el 14 de julio de 2025 por incumplimiento del requisito mínimo del precio de oferta. Las acciones de la compañía se han negociado por debajo del precio mínimo de oferta de $1.00 durante 30 días hábiles consecutivos.

La empresa biotecnológica ha recibido un período de cumplimiento de 180 días hasta el 12 de enero de 2026 para corregir esta situación. Virax podrá cumplir si su acción mantiene un precio de cierre de al menos $1.00 durante un mínimo de 10 días hábiles consecutivos. Si no lo logra, podría ser elegible para un período adicional de gracia de 180 días. Mientras tanto, las acciones de VRAX seguirán cotizando en Nasdaq sin interrupción.

Virax Biolabs (NASDAQ: VRAX)ëŠ� 2025ë…� 7ì›� 14ì� 나스닥으로부í„� 최저 ìž…ì°°ê°€ 요건 ë¯¸ì¶©ì¡±ì— ëŒ€í•� 통지ë¥� 받았습니ë‹�. 회사ì� 주ì‹ì€ ì—°ì† 30 거래ì� ë™ì•ˆ 최소 ìž…ì°°ê°€ $1.00 ì´í•˜ë¡� 거래ë˜ì—ˆìŠµë‹ˆë‹�.

ì� ìƒëª…공학 회사ëŠ� 2026ë…� 1ì›� 12ì¼ê¹Œì§€ 180ì¼ì˜ 준ìˆ� 기간ì� 부여받ì•� 규정ì� 회복해야 합니ë‹�. ViraxëŠ� 주ì‹ì� 최소 10 거래ì� ì—°ì†ìœ¼ë¡œ 종가 기준 $1.00 ì´ìƒì� 유지하면 준ìˆ� 요건ì� 충족í•� ìˆ� 있습니다. 만약 실패í•� 경우, 추가 180ì¼ì˜ 유예 기간ì� ë°›ì„ ìžê²©ì� ìžˆì„ ìˆ� 있습니다. ê·¸ë™ì•� VRAX 주ì‹ì€ 나스닥ì—ì„� 중단 ì—†ì´ ê³„ì† ê±°ëž˜ë©ë‹ˆë‹�.

Virax Biolabs (NASDAQ : VRAX) a reçu une notification de Nasdaq le 14 juillet 2025 concernant le non-respect de l'exigence de prix d'offre minimum. L'action de la société s'est négociée en dessous du prix d'offre minimum de 1,00 $ pendant 30 jours ouvrables consécutifs.

La société biotechnologique a obtenu une période de conformité de 180 jours jusqu'au 12 janvier 2026 pour revenir en conformité. Virax pourra se conformer si son action maintient un cours de clôture d'au moins 1,00 $ pendant au moins 10 jours ouvrables consécutifs. En cas d'échec, la société pourrait bénéficier d'une période de grâce supplémentaire de 180 jours. Pendant ce temps, les actions VRAX continueront d'être négociées sur le Nasdaq sans interruption.

Virax Biolabs (NASDAQ: VRAX) erhielt am 14. Juli 2025 eine Mitteilung von der Nasdaq wegen Nichteinhaltung der Mindestgebotspreisanforderung. Die Aktie des Unternehmens wurde an 30 aufeinanderfolgenden Handelstagen unter dem erforderlichen Mindestgebotspreis von 1,00 $ gehandelt.

Das Biotechnologieunternehmen hat eine 180-tägige Nachfrist bis zum 12. Januar 2026 erhalten, um die Anforderungen wieder zu erfüllen. Virax kann die Anforderungen erfüllen, wenn der Schlusskurs der Aktie mindestens 10 aufeinanderfolgende Handelstage lang bei mindestens 1,00 $ liegt. Sollte dies nicht gelingen, könnte das Unternehmen für eine zusätzliche 180-tägige Schonfrist infrage kommen. In der Zwischenzeit werden die VRAX-Aktien ohne Unterbrechung an der Nasdaq gehandelt.

Positive
  • Potential eligibility for additional 180-day grace period if initial compliance period is not met
  • Company's shares continue trading on Nasdaq without immediate delisting risk
Negative
  • Stock price has fallen below $1.00 minimum bid requirement
  • Risk of potential delisting from Nasdaq if compliance is not achieved by January 12, 2026
  • Company must achieve significant stock price increase to maintain listing

LONDON, July 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced that it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") dated July 14, 2025, notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2)(the "Minimum Bid Price Rule") for continued listing on the NASDAQ. 

NASDAQ Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of one hundred eighty (180) calendar days, or until January 12, 2026 (the "Compliance Period"), to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the Compliance Period, the closing bid price per share of the Company's ordinary shares is at least $1.00 for a minimum of ten (10) consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed. In the event the Company does not regain compliance by January 12, 2026, the Company may be eligible for an additional 180 calendar day grace period.

The Nasdaq notification letter does not result in the immediate delisting of the Company's ordinary shares, and the shares will continue to trade uninterrupted under the symbol "VRAX."

About Virax Biolabs Group Limited.

Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.

For more information, please visit .

Caution Concerning Forward Looking Statements:

This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. These forward-looking statements are based on information currently available to Virax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Virax's Annual Report on Form 20-F for the year ended March 31, 2025. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Cision View original content to download multimedia:

SOURCE Virax BioLabs Group Limited

FAQ

Why did Virax Biolabs (VRAX) receive a Nasdaq deficiency notice?

Virax received the notice because its stock price traded below the required $1.00 minimum bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).

What is the deadline for Virax Biolabs to regain Nasdaq compliance?

Virax has until January 12, 2026 (180 calendar days) to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.

Will VRAX stock be delisted immediately from Nasdaq?

No, VRAX shares will continue trading on Nasdaq under the symbol 'VRAX' during the compliance period. The notification does not result in immediate delisting.

What happens if Virax Biolabs doesn't meet the January 2026 deadline?

If Virax fails to regain compliance by January 12, 2026, it may be eligible for an additional 180-day grace period to meet the minimum bid requirement.

How can Virax Biolabs regain Nasdaq compliance?

Virax can regain compliance if its stock maintains a closing bid price of at least $1.00 for a minimum of 10 consecutive business days during the compliance period.
Virax Biolabs Group Ltd

NASDAQ:VRAX

VRAX Rankings

VRAX Latest News

VRAX Latest SEC Filings

VRAX Stock Data

3.36M
3.90M
10.08%
6.06%
0.34%
Biotechnology
Healthcare
United Kingdom
Lanarkshire